These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8198043)

  • 1. Pravastatin, lipids, and major coronary events.
    Furberg CD; Byington RP; Crouse JR; Espeland MA
    Am J Cardiol; 1994 Jun; 73(15):1133-4. PubMed ID: 8198043
    [No Abstract]   [Full Text] [Related]  

  • 2. Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin.
    Kesteloot H; Claeys G; Blanckaert N; Lesaffre E
    Acta Cardiol; 1997; 52(2):107-16. PubMed ID: 9187418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time course of serum lipid and lipoprotein levels after coronary bypass surgery: modification by pravastatin.
    Kesteloot H; Cobbaert C; Meyns B; Szécsi J; Lesaffre E; Sergeant P
    Acta Cardiol; 1992; 47(6):519-28. PubMed ID: 1290313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.
    Tonkin AM; Colquhoun D; Emberson J; Hague W; Keech A; Lane G; MacMahon S; Shaw J; Simes RJ; Thompson PL; White HD; Hunt D
    Lancet; 2000 Dec; 356(9245):1871-5. PubMed ID: 11130382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).
    Byington RP; Furberg CD; Crouse JR; Espeland MA; Bond MG
    Am J Cardiol; 1995 Sep; 76(9):54C-59C. PubMed ID: 7572688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Am J Cardiol; 2010 Sep; 106(6):787-92. PubMed ID: 20816118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico).
    Ital Heart J; 2000 Dec; 1(12):810-20. PubMed ID: 11302109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
    McPherson R; Bedard J; Connelly P; Curnew G; Davignon J; Echenberg D; Lavin P; Leiter L; Lenis J; McQueen M
    Clin Ther; 1992; 14(2):276-91. PubMed ID: 1611649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
    Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels?
    Maron DJ
    Nat Clin Pract Cardiovasc Med; 2004 Nov; 1(1):18-9. PubMed ID: 16265253
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparative study of gemfibrozil versus pravastatin in the treatment of patients with coronary artery disease and low HDL cholesterol levels].
    Santos RD; Mansur AP; Safi Júnior J; Giraldez RR; Maranhão RC; Pileggi F; Ramires JA
    Arq Bras Cardiol; 1995 Aug; 65(2):181-3. PubMed ID: 8554498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in lipid status during pravastatin treatment].
    Craveri A; Colombo L; Citella C; Pedrazzini L; Altomare S; Giavardi L; Picollo S; Vignati A; Lanfredini M
    Minerva Med; 1992 Nov; 83(11):695-703. PubMed ID: 1461540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
    Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J
    Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of serum Lp(a) in men after coronary artery bypass grafting.
    Cobbaert C; Sergeant P; Meyns B; Szécsi J; Kesteloot H
    Acta Cardiol; 1992; 47(6):529-42. PubMed ID: 1290314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol reduction and coronary prevention.
    Prabhakaran D
    Natl Med J India; 1997; 10(1):24-5. PubMed ID: 9069704
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.